Stephens Cuts OraSure Technologies (NASDAQ:OSUR) Price Target to $3.00

OraSure Technologies (NASDAQ:OSUR) had its price target reduced by Stephens from $3.50 to $3.00 in a research note published on Wednesday,Benzinga reports. They currently have an equal weight rating on the medical instruments supplier’s stock.

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of OraSure Technologies in a report on Wednesday, October 8th. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, OraSure Technologies currently has an average rating of “Reduce” and a consensus target price of $3.00.

OraSure Technologies Stock Up 1.3%

OSUR stock opened at $2.31 on Wednesday. The company’s 50-day simple moving average is $2.98 and its 200-day simple moving average is $2.97. OraSure Technologies has a 52-week low of $2.20 and a 52-week high of $4.22. The firm has a market cap of $165.71 million, a P/E ratio of -3.45 and a beta of 0.54.

OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings results on Wednesday, November 5th. The medical instruments supplier reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.03. OraSure Technologies had a negative return on equity of 10.81% and a negative net margin of 36.84%.The firm had revenue of $27.09 million during the quarter, compared to analyst estimates of $28.96 million. OraSure Technologies has set its Q4 2025 guidance at EPS. On average, analysts anticipate that OraSure Technologies will post -0.08 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of OraSure Technologies in the 1st quarter valued at approximately $49,000. Private Management Group Inc. acquired a new stake in OraSure Technologies in the first quarter valued at $14,886,000. XTX Topco Ltd boosted its holdings in OraSure Technologies by 145.0% in the first quarter. XTX Topco Ltd now owns 120,191 shares of the medical instruments supplier’s stock valued at $405,000 after purchasing an additional 71,126 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in OraSure Technologies by 7.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 619,835 shares of the medical instruments supplier’s stock worth $2,089,000 after acquiring an additional 41,067 shares in the last quarter. Finally, Gagnon Securities LLC purchased a new position in shares of OraSure Technologies during the first quarter worth about $3,619,000. 93.50% of the stock is currently owned by hedge funds and other institutional investors.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.